Bio­Marin may have lost the bat­tle in DMD ri­val­ry, but it won a $35M ar­gu­ment with Sarep­ta

Bio­Marin $BM­RN may have lost big on their ex­pen­sive and high-pro­file bid to get an OK for a trou­bled Duchenne mus­cu­lar dy­s­tro­phy drug, but the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.